LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Kodu・Aktsiate loetelu・Cytek Biosciences Inc

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.93 7.17

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.6

Max

4.98

Põhinäitajad
By Trading Economics
Sissetulek	-39M -44M
Müük	9.8M 62M
Kasumimarginaal	-70.929
Töötajad	702
EBITDA	4M -263K

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+34.12% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	40M 602M
Eelmine avamishind	-2.24
Eelmine sulgemishind	4.93

Uudiste sentiment

By Acuity

50%

187 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.7 / 3.8 Toetus ja vastupanu

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. mai 2026, 23:41 UTC

Tulu

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. mai 2026, 21:40 UTC

Tulu

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. mai 2026, 23:12 UTC

Tulu

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. mai 2026, 23:11 UTC

Tulu

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:07 UTC

Tulu

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. mai 2026, 23:05 UTC

Tulu

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. mai 2026, 23:04 UTC

Tulu

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. mai 2026, 22:50 UTC

Tulu

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. mai 2026, 21:58 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:47 UTC

Market Talk

Tulu

Costco Posts 13% Sales Growth in April -- Market Talk

6. mai 2026, 21:46 UTC

Tulu

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. mai 2026, 21:40 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. mai 2026, 21:32 UTC

Kuumad aktsiad

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. mai 2026, 21:29 UTC

Tulu

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

34.12% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD 34.12%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Cytek Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

187 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.